Röth, Alexander <br/><br/>
Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.  [electronic resource] 

 -  Blood advances  09 2018 
 - 2176-2185 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2473-9537 
<br/><br/><label>Standard No.: </label>10.1182/bloodadvances.2018020644  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Complement C5--antagonists & inhibitors<br/>Female<br/>Hemoglobinuria, Paroxysmal--drug therapy<br/>Hemolysis--drug effects<br/>Humans<br/>L-Lactate Dehydrogenase--blood<br/>Male<br/>Middle Aged<br/>Quality of Life<br/>Treatment Outcome